CD137/FAP bispecific agonist antibody (Boehringer Ingelheim International)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug NameCD137/FAP bispecific agonist antibody (Boehringer Ingelheim International)
Drug Alias Namedual 4-1BB costimulatory/FAP agonist bispecific antibody (Boehringer Ingelheim)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 agonistsFibroblast activation protein alpha modulators
TargetsProlyl endopeptidase FAPTumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesBoehringer Ingelheim International Gmbh
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A